Literature DB >> 33877855

Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.

Yasuhisa Hasegawa1, Kiyoaki Tsukahara2, Seiichi Yoshimoto3, Kouki Miura4, Junkichi Yokoyama5, Shigeru Hirano6, Hirokazu Uemura7, Masashi Sugasawa8, Tomokazu Yoshizaki9, Akihiro Homma10, Kazuaki Chikamatsu11, Mikio Suzuki12, Akihiro Shiotani13, Takashi Matsuzuka1,14, Naoyuki Kohno15, Masakazu Miyazaki16, Isao Oze17, Keitaro Matsuo17, Shigeru Kosuda18, Yasushi Yatabe3.   

Abstract

PURPOSE: This study aimed to compare patients with early oral cavity squamous cell carcinoma (OCSCC) (tumor category [T] 1-2, node-negative, and no distant metastasis) treated with traditional elective neck dissection (ND) with those managed by sentinel lymph node biopsy (SLNB) using survival and neck function and complications as end points.
METHODS: Sixteen institutions in Japan participated in the study (trial registration number: UMIN000006510). Patients of age ≥ 18 years with histologically confirmed, previously untreated OCSCC (Union for International Cancer Control TNM Classification of Malignant Tumors 7th edition T1-2, node-negative no distant metastasis), with ≥ 4 mm (T1) depth of invasion, were randomly assigned to undergo standard selective ND (ND group; n = 137) or SLNB-navigated ND (SLNB group; n = 134). The primary end point was the 3-year overall survival rate, with a 12% noninferiority margin; secondary end points included postoperative neck functionality and complications and 3-year disease-free survival. Sentinel lymph nodes underwent intraoperative multislice frozen section analyses for the diagnosis. Patients with positive sentinel lymph nodes underwent either one-stage or second-look ND.
RESULTS: Pathologic metastasis-positive nodes were observed in 24.8% (34 of 137) and 33.6% (46 of 134) of patients in the ND and SLNB groups, respectively (P = .190). The 3-year overall survival in the SLNB group (87.9%; lower limit of one-sided 95% CI, 82.4) was noninferior to that in the ND group (86.6%; lower limit 95% CI, 80.9; P for noninferiority < .001). The 3-year disease-free survival rate was 78.7% (lower limit 95% CI, 72.1) and 81.3% (75.0) in the SLNB and ND groups, respectively (P for noninferiority < .001). The scores of neck functionality in the SLNB group were significantly better than those in the ND group.
CONCLUSION: SLNB-navigated ND may replace elective ND without a survival disadvantage and reduce postoperative neck disability in patients with early-stage OCSCC.

Entities:  

Mesh:

Year:  2021        PMID: 33877855     DOI: 10.1200/JCO.20.03637

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  6 in total

1.  Detection of sentinel lymph nodes by tilmanocept in oral squamous cell carcinoma.

Authors:  Remco de Bree; Rutger Mahieu; Dominique N V Donders; Bart de Keizer
Journal:  Clin Exp Metastasis       Date:  2022-02-22       Impact factor: 5.150

Review 2.  Critical Review of the Current Evidence on Sentinel Node Biopsy in Oral Cancer.

Authors:  Arjun Singh; Satadru Roy; Vidisha Tuljapurkar; Deepa Nair; Pankaj Chaturvedi
Journal:  Curr Oncol Rep       Date:  2022-03-17       Impact factor: 5.075

3.  Sentinel node biopsy or elective neck dissection in early oral cancer: a point of contention.

Authors:  Abhijeet Singh; Anand Subash; Piyush Sinha
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-08       Impact factor: 2.503

4.  Ultrasound accurately assesses depth of invasion in T1-T2 oral tongue cancer.

Authors:  Olof Nilsson; Johan Knutsson; Fredrik J Landström; Anders Magnuson; Mathias von Beckerath
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-08-24

5.  Predictive factors for false negatives following sentinel lymph node biopsy in early oral cavity cancer.

Authors:  Kouki Miura; Daisuke Kawakita; Isao Oze; Motoyuki Suzuki; Masashi Sugasawa; Kazuhira Endo; Tomohiro Sakashita; Shinichi Ohba; Mikio Suzuki; Akihiro Shiotani; Naoyuki Kohno; Takashi Maruo; Chiaki Suzuki; Takehiro Iki; Nao Hiwatashi; Fumihiko Matsumoto; Kenya Kobayashi; Minoru Toyoda; Kenji Hanyu; Yusuke Koide; Yoshiko Murakami; Yasuhisa Hasegawa
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

6.  CT Lymphography Using Lipiodol® for Sentinel Lymph Node Biopsy in Early-Stage Oral Cancer.

Authors:  Rutger Mahieu; Dominique N V Donders; Jan Willem Dankbaar; Remco de Bree; Bart de Keizer
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.